

#134

COMPLETE

Collector: Web Link 1 (Web Link)
Started: Monday, September 08, 2025 7:35:47 PM
Last Modified: Monday, September 08, 2025 8:05:57 PM
Time Spent: 00:30:10
IP Address: 99.252.61.208

Page 2: Part 1

Q1

Title of activity

CSACI ASM 2025

Q2

Date of activity

October 18, 2025

Q3

What is your role in the CPD activity? (Select all that apply)

Speaker,
Author / Co-Author

Q4

What's your practice type?

Academic Practice

Q5

Please indicate:

I HAVE a relationship with a for-profit and/or a not-for-profit organization to disclose.If so, please indicate below (questions 5 to 10) the organization(s) with which you have/had a relationship over the previous two years and briefly describe the nature of that relationship.

Q6

Any direct financial payments including receipt of honoraria

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)

AZ, GSK, Novartis, CSL Behring, Pfizer, Sanofi, Takeda, Medexus, AbbVie, MiravoHealth, Alk, Leo, Celltrion, BioCryst, Viatrix

Description of relationship(s)

Consultancy, honoraria

Q7

Membership on advisory boards or speakers' bureaus

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)

AZ, GSK, Novartis, CSL Behring, Pfizer, Sanofi, Takeda, Medexus, AbbVie, MiravoHealth, Alk, Leo, Celltrion, BioCryst, Viartis, Food Allergy Canada, CHAEN, Asthma Canada, CAAIF, Schroeder Allergy and Immunology Research Institute (unfunded)

Description of relationship(s)

Pharma-advisory boards, FAC-medical advisor (unfunded), CHAEN and Asthma Canada-BOD (unfunded), CAAIF-President (unfunded), Director Schroeder Allergy and Immunology Research Institute (unfunded)

Q8

Funded grants or clinical trials

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)

Sean Delaney Foundation, Schroeder Allergy and Immunology Research Institute, ALK, CSL Behring, Takeda

Description of relationship(s)

PI or collaborator on Allergy related research, CSL Behring/Takeda-collaborator clinical trial

Q9

Respondent skipped this question

Patents on a drug, product or device

Q10

Respondent skipped this question

All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity

Page 3: Part 2: To be completed by presenters only

Q11

No

I intend to use trade names during my presentation. Note: Only generic names should be used whenever possible. If trade names are used, they should be accompanied by the generic name.

Q12**No**

I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. "off-label" use of medication). Note: You must declare all off-label use to the audience during your presentation.

Q13**Respondent skipped this question**

If you answered "Yes" to the previous question, are the medications recommended manufactured by companies you have received funding from?

Q14**Yes**

I acknowledge that the National Standard requires that any description of therapeutic options utilize generic names (or both generic and trade names) and not reflect exclusivity and branding.

Page 4: Part 3 (Anonymous & Optional): Equity, Diversity and Inclusion (EDI)

Q15**Respondent skipped this question**

I confirm that I've completed the EDI Survey linked above

Page 5: PART 4: Acknowledgement and signature (for all)

Q16

First Name:

Susan

Q17

Last Name:

Waserman

Q18**She/Her**

Gender Pronouns - How would you like us to address you?

Q19

Please review and check the items below.

I confirm that the above information is accurate and complete.

,

I understand that this information may be publicly available
